Treatment for hepatitis C virus-induced portal hypertension in leukemic children

Area of Science:

• Pediatric Oncology
• Hepatology
• Infectious Diseases

Background:

• Children with acute leukemia face high risks of hepatitis C virus (HCV) infection due to immunosuppression and blood transfusions.
• HCV infection in these patients can lead to serious complications like portal hypertension, liver cirrhosis, and hepatocellular carcinoma.
• Managing HCV-related complications is crucial for the long-term health of leukemia survivors.

Purpose of the Study:

• To evaluate the efficacy of amlodipine in managing portal hypertension in children with acute lymphoblastic leukemia (ALL) and HCV infection.
• To assess the safety of amlodipine treatment during maintenance chemotherapy for ALL.

Main Methods:

• A randomized controlled trial involving 60 male children with ALL in remission and confirmed HCV infection.
• Patients were divided into three groups: amlodipine treatment (5 mg/day for 4 weeks), placebo, and a control group.
• Portal blood pressure was monitored, and HCV infection was confirmed using real-time PCR.

Main Results:

• Amlodipine significantly reduced elevated portal blood pressure to normal levels (p ≤ 0.001).
• The dosage of amlodipine used did not interfere with the efficacy of chemotherapy.
• No adverse effects on the chemotherapy's mechanism of action were observed.

Conclusions:

• Amlodipine is an effective and safe treatment for controlling portal hypertension in pediatric leukemia patients with HCV infection.
• Proper screening of the blood transfusion pool can help prevent HCV transmission in leukemic patients.
• Further research could explore long-term outcomes and optimal dosing strategies for amlodipine in this population.